CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 106 enrolled
Drug / intervention
BMS-986016 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02061761
NCT02061761Phase 2Completed
CompareCT.gov

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (Relatlimab, BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies

Bristol-Myers Squibb·interventional·Posted Feb 13, 2014·Updated Mar 24, 2023

In Brief

A Phase 2 clinical trial evaluating BMS-986016 and BMS-936558 for Hematologic Neoplasms. Completed, enrolled 106 participants across 10 sites in 2 countries.

Detailed Summary

The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with relapsed or refractory B-cell malignancies. Co-primary objective is to investigate the preliminary efficacy of relatlimab in combination with nivolumab in subjects with relapsed or refractory Hodgkin lymphoma (HL), and relapsed or refractory Diffused Large B Cell lymphoma (DLBCL)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Neoplasms
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 13, 2014
Enrollment StartMar 13, 2014
Primary CompletionFeb 16, 2022
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 12.4 years ago

Interventions

BMS-986016biological

Specified Dose on Specified Days

BMS-936558biological

Specified Dose on Specified Days